Former Senior Vice President and Chief Medical Officer · CytomX Therapeutics, Inc. (CTMX)

Rachel Humphrey

A named executive officer of CytomX Therapeutics in every fiscal year CompBrief holds from FY2016 to FY2019. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2019

$1,871,354

Salary $289,761Stock awards $0

FY2018: $2,290,819

3rd of 6 named executive officers at CytomX Therapeutics by FY2019 total.

6 named officers on file for CytomX Therapeutics, FY2019

Rachel Humphrey’s pay file — $29

  • 4 fiscal years of pay, line by line
  • 2 equity grants, each cited to its filing
  • CTMX’s disclosed peer group of 21 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how CytomX Therapeutics’s whole pay program stands against its peers

  • CytomX Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on CTMX→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 29, 2020 (DEF 14A).

Free

Get Rachel Humphrey’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Rachel Humphrey compensation by year

CytomX Therapeutics Summary Compensation Table · all 4 fiscal years held
In US dollars, as CytomX Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2016FY2017FY2018FY2019
Salary$395,000$410,800$440,448$289,761
Bonus$0$0$0$0
Stock awards$0$0$0$0
Option awards$639,412$884,472$1,504,760$858,654
Non-equity incentive$193,550$244,426$220,224$0
Pension and deferred compensation$0$0$0$0
All other$34,072$69,647$125,387$833,897
Total$1,262,034$1,609,345$2,290,819$1,871,354

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: CytomX Therapeutics, Inc. DEF 14A filed April 29, 2020, accession 0001140361-20-010142, and prior-year filings. Open the filing on EDGAR.

How this page was built: the CytomX Therapeutics, Inc. filed document, accession 0001140361-20-010142. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2020.

$1.3M
$1.6M
$2.3M
$1.9M
FY16
FY17
FY18
FY19
SalaryNon-equity incentiveOption awardsAll other

CytomX Therapeutics’s named executive officers, FY2019

as the company reported each
Named executive officerRoleFY2019 total
D. Sean A. McCarthyChief Executive Officer and Chairman of the Board of Directors$3,769,930
Amy PetersonExecutive Vice President, Chief Development Officer$3,395,723
Rachel Humphrey · this pageFormer Senior Vice President and Chief Medical Officer$1,871,354
W. Michael KavanaughFormer Senior Vice President, Chief Science Officer and Head of Research and Non-Clinical Development$1,476,997
Lloyd RowlandSenior Vice President, General Counsel, Chief Compliance Officer and Secretary$1,097,843
Debanjan RayFormer Senior Vice President and Chief Financial Officer$1,063,677

The full CytomX Therapeutics compensation record

free company brief

This page is one person within CytomX Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the CytomX Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are CytomX Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Rachel Humphrey's compensation dossier · One-time report. No refunds.